Page last updated: 2024-10-20

phthalic acid and Glycogen Storage Disease Type II

phthalic acid has been researched along with Glycogen Storage Disease Type II in 1 studies

phthalic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7178
phthalic acid : A benzenedicarboxylic acid cosisting of two carboxy groups at ortho positions.

Glycogen Storage Disease Type II: An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)

Research Excerpts

ExcerptRelevanceReference
"The life expectancy of Pompe disease patients has increased due to improved neonatal screening and enzyme replacement therapy."1.91Precocious puberty in patients with Pompe disease. ( Chen, MH; Chien, YH; Tsai, MM; Tung, YC, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Tsai, MM1
Chen, MH1
Chien, YH1
Tung, YC1

Other Studies

1 other study available for phthalic acid and Glycogen Storage Disease Type II

ArticleYear
Precocious puberty in patients with Pompe disease.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adult; Cross-Sectional Studies; Enzyme Replacement Therapy; Glycogen Storage Disease Type II; Humans

2023